Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Efpeglenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms AMPLITUDE-O
- Sponsors Sanofi
- 20 Feb 2023 Results exploring relationship between Efpeglenatide dose and cardiovascular outcomes during follow-up of 1.8 years published in the Circulation
- 10 Apr 2022 This trial has been completed in Spain (Date of the global end of the trial : 10-Dec-2020), according to European Clinical Trials Database record.
- 15 Nov 2021 Results assessing impact of SGLT2i on the efficacy (primary and secondary endpoints, including heart failure and renal events) and safety of efpeglenatide, presented at the American Heart Association Scientific Sessions 2021